Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with Hepatocellular Carcinoma (HCC) before major hepatic resection or radiofrequency ablation (RFA).

Clinical Trial Description

1. Preoperative/RFA assessment of remnant liver function is important for avoiding posthepatectomy liver failure. However, the function of the future remnant is decreased in patients with chronic liver disease or cirrhosis, compared to that of healthy patients with an equal volume. Therefore, volume-based estimation of hepatic reserve function is inadequate for patients with hepatic dysfunction.

2. Standard clinical liver function tests, such as ICG clearance rate or Child-Pugh score, provides measurements of the global hepatic function, but cannot evaluate the functional distribution in the liver. Gd-EOB-DTPA (Gadoxetic acid, Primovist®, Bayer Schering) enhanced MRI has been recently demonstrated to have the potential to be an imaging-based liver function test, with the possibility to detect functional differences on a regional or even segmental level.

3. Gd-EOB-DTPA-enhanced liver MRI may be able to assess not only global but also segmental liver function in patients with hepatocellular carcinoma (HCC) who have a relatively high risk for developing liver failure after surgical resection due to coexistent hepatic damage by chronic viral hepatitis and/or cirrhosis preoperatively.

The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with HCC before major hepatic resection/RFA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01490203
Study type	Observational
Source	Seoul National University Hospital
Contact
Status	Completed
Phase
Start date	December 2011
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03289533` - A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)	Phase 1
Terminated	`NCT01141478` - Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria	N/A
Recruiting	`NCT05580835` - PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma	N/A
Active, not recruiting	`NCT05389527` - Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT04560751` - TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Withdrawn	`NCT02939807` - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	Phase 2
Completed	`NCT01915602` - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2
Completed	`NCT04970212` - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting	`NCT02403544` - Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma	Phase 1
Completed	`NCT01897038` - A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma	Phase 1
Terminated	`NCT01337492` - Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)	Phase 0
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Completed	`NCT01003015` - Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma	Phase 2
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Completed	`NCT00559455` - Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT00384800` - A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)	Phase 2
Terminated	`NCT00582400` - A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver	Phase 2
Completed	`NCT00056992` - Testing of ADI-PEG in Hepatocellular Carcinoma	Phase 2
Completed	`NCT02859324` - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)	Phase 1/Phase 2
Terminated	`NCT02439008` - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma — LiFE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms